Streptococcal streptolysin S vaccines
View Patent ↗Provided are streptolysin S (SLS) polypeptides, peptides, and variants thereof, antibodies directed thereto, and isolated nucleic acids encoding such proteins. In one embodiment, a method is provided wherein a synthetic peptide of SLS is used to elicit an immune response specific for SLS in a subject to treat or prevent a streptococcal infection. In other embodiments, antibodies that neutralize the hemolytic activity of the SLS toxin may be used as a vaccinating agent.
1. A composition, comprising a pharmaceutically acceptable carrier and a peptide immunogen for eliciting an immune response in a subject, wherein the amino acid sequence of the peptide immunogen is at least 80% identical to the amino acid sequence set forth in SEQ ID NO: 6, wherein the peptide immunogen has at least one streptolysin S epitope, and wherein the peptide immunogen elicits an antibody that neutralizes hemolytic activity of streptolysin S.
2. A composition comprising a pharmaceutically acceptable carrier and a peptide immunogen for eliciting an immune response in a subject, wherein the peptide immunogen consists of the amino acid sequence set forth in SEQ ID NO:6.
3. The composition of claim 1 wherein the amino acid sequence of the peptide immunogen is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 6.
4. The composition according to claim 1 wherein the amino acid sequence of the peptide immunogen is at least 95% identical to the amino acid sequence set forth in SEQ ID NO: 6.
5. The composition according to any one of claims 1 , 3 , and 4 further comprising a second immunogen that comprises a hybrid multivalent M polypeptide.
6. The composition according to claim 5 wherein the peptide immunogen is linked to the hybrid multivalent M polypeptide.
7. The composition according to claim 6 wherein the peptide immunogen and the multivalent M polypeptide are linked recombinantly or chemically.
8. The composition according to claim 5 wherein the peptide immunogen and multivalent M polypeptide are recombinant or synthetic.
9. The composition according to any one of claims 1 , 3 , and 4 wherein the subject is a human or an animal.
10. The composition according to any one of claims 1 , 3 , and 4 further comprising an adjuvant.
11. The composition according to claim 10 wherein the adjuvant is alum or Freund's.
12. The composition according to claim 1 wherein the composition is sterile.
13. The composition according to claim 2 comprising a second immunogen that comprises a hybrid multivalent M polypeptide.
14. The composition according to claim 13 , wherein the peptide immunogen is linked to the hybrid multivalent M polypeptide.
15. The composition according to claim 14 , wherein the peptide immunogen and the multivalent M polypeptide are linked recombinantly or chemically.
16. The composition according any one of claims 13 – 15 wherein the peptide immunogen and multivalent M polypeptide an recombinant or synthetic.
17. The composition according to either claim 2 or claim 13 wherein the subject is a human or an animal.
18. The composition according to either claim 2 or claim 13 further comprising an adjuvant.
19. The composition according to claim 18 , wherein the adjuvant is alum or Freund's.
20. The composition according to either claim 2 or claim 13 , wherein the composition is sterile.
21. The composition according to claim 2 , wherein the peptide immunogen elicits an anti-streptolysin S neutralizing antibody.